"file" "checksum"
"content/step_1/conceptsetdataset.Rmd" "8e7d557aa951af5854e0e7ab6bc3c88d"
"content/step_1/D3_clean_spells.Rmd" "39e09b99d89e7b3537c164bc9d2a2be7"
"content/step_1/D3_output_spells_category.Rmd" "40d5720889ca0b1c30649bd456935ec4"
"content/step_1/D3_persons.Rmd" "57deb3bd88e858d2b99328577fdfb7be"
"content/step_1/D3_selection_criteria_from_PERSONS_to_study_population.Rmd" "25a3538b5885f486b9225e182bf6a626"
"content/step_1/itemsetdataset.Rmd" "a98c678630f024d23abc30160b516d9c"
"content/step_1/promptsetdataset.Rmd" "a8712361dfb4ce32a2ce2a713387da82"
"content/step_10/D4_DU_individual_prevalence_of_use_MSmeds_in_MSpregnancy_trimesters.Rmd" "4f8fa32a307e76f9654077b8a3391adb"
"content/step_10/D4_DU_prevalence_MS_in_pregnancy_cohort.Rmd" "491a7c73e434282689d492f4fc8147c2"
"content/step_10/D4_DU_prevalence_of_exclusive_use_MSmeds_in_MSpregnancy_trimesters.Rmd" "a4b61a6702e2ff2b114bd187e241a3ad"
"content/step_10/D4_DU_prevalence_of_use_MSdrugs_in_MS_cohort.Rmd" "2d33360f65fee20b91d8c3228493ba0d"
"content/step_10/D4_DU_prevalence_of_use_MSdrugs_in_MSpregnancy_cohort.Rmd" "a0e4049257beef4f9e1e4cc748040279"
"content/step_11/D5_DU_for_Template_3.Rmd" "3c783ad5fb23a86afa2238db272d21fe"
"content/step_11/D5_DU_for_Template_4.Rmd" "d54af5b75ec137711153896c9b233570"
"content/step_11/D5_DU_for_Template_5.Rmd" "65d2e3734d9effd579fdd8c9917911fa"
"content/step_11/D5_DU_for_Template_6.Rmd" "674eb57c31af8d824aeb223e2d0a8749"
"content/step_11/D5_DU_for_Template_7.Rmd" "2a83eefb6b0ae568f442b7b8a64caaa3"
"content/step_11/D5_DU_for_Templats_8_11.Rmd" "a6e27cebbcd76a76e12c3cdc1ec591c5"
"content/step_2/D4_study_population_SAP1.Rmd" "f634de289133c4dcdea2c5aaae03958d"
"content/step_2/Flowchart_exclusion_criteria.Rmd" "8ae91f3f8400ca19bfdbda466db20812"
"content/step_2/Flowchart_exclusion_criteria_masked.Rmd" "091d24c614909b973d765e051cde2d6e"
"content/step_3/D3_algorithms_MS.Rmd" "29d41d0e42f04a85e5f31dc7d6f923d0"
"content/step_3/D3_algorithms_multiple_lookback_MS.Rmd" "80eca94c13267e13ae1664dd5abef13e"
"content/step_3/D3_components_MS_SAP1.Rmd" "5324f8c4a9cb8f5c488b6bcca94a10f8"
"content/step_3/D3_components_multiple_lookback_MS.Rmd" "cba72760592972d7aaba4a8fe97ff48f"
"content/step_3/D3_drug_proxies_cleaned.Rmd" "72999206859a678a134c72e8ea528480"
"content/step_3/D3_main_components.Rmd" "c2baf5bfe77df5529afd6d808057c493"
"content/step_3/D3_outcomes_cleaned.Rmd" "d687ef9ed536b0a1eb53d3b3d77d3dc4"
"content/step_3/D3_study_population_SAP1.Rmd" "9d10120d46ec62fc5e8e45b80f73ea97"
"content/step_3/D4_prevalence_aggregated_multiple_lookback_MS.Rmd" "94ca5ede751cba7eb8b0ab8587ba6536"
"content/step_3/D4_prevalence_aggregated_multiple_lookback_MS_summary_level.Rmd" "80b3154bc5053277ff7e26127b32746d"
"content/step_3/D4_prevalence_average_point_MS.Rmd" "0b995b0398a1d278553bbcbeaa59f356"
"content/step_3/D4_prevalence_average_point_MS_summary_levels.Rmd" "5633fb2302ee984ce23bc62ff512dff6"
"content/step_3/D4_prevalence_period_MS.Rmd" "fc2a948b4c79c390a3468d8acdb379f4"
"content/step_3/D4_prevalence_period_MS_summary_levels.Rmd" "cc29ca73f19076c13aafc31897c3135b"
"content/step_3/D4_prevalence_persontime_MS.Rmd" "8f795979971b94712e42c4c37b652cba"
"content/step_3/D4_prevalence_persontime_MS_summary_level.Rmd" "f1e1fa9d54a7069255ea9b0f0f283eef"
"content/step_3/D5_meaning_occurences.Rmd" "c9ab80ae6c7bcb32f1edd8090d1c0f6c"
"content/step_3/D5_meaning_occurences_masked.Rmd" "6b4ed0694dba04efffef9f00caa14e34"
"content/step_4/D5_N_women_and_ranges_MS.Rmd" "b59a9e57b68d895466e5cfc23d7cb488"
"content/step_4/D5_N_women_and_ranges_MS_masked.Rmd" "8cc90992b3df843c026f8419735ebfe3"
"content/step_4/D5_prevalence_aggregated_all.Rmd" "99d1f6156614358275aa1f91001728ab"
"content/step_4/D5_prevalence_aggregated_all_masked.Rmd" "6bc191a89aab8c65c702dcdaa1d0663c"
"content/step_4/D5_prevalence_aggregated_multiple_lookback.Rmd" "b9e4bbbea9bcb4a2a69261af80a00edd"
"content/step_4/D5_prevalence_aggregated_multiple_lookback_masked.Rmd" "7c73660f8377057bd9fbccdce72b3742"
"content/step_4/D5_prevalence_average_point.Rmd" "ccbcaae4687a9aae5279311de4ef24e7"
"content/step_4/D5_prevalence_average_point_masked.Rmd" "38ca9a52031444a8c9f121dc09148929"
"content/step_4/D5_prevalence_period.Rmd" "e12079f81024549a2f19d695a2af28f6"
"content/step_4/D5_prevalence_period_masked.Rmd" "e5982b6257e92f2362e378f9cbfa94e1"
"content/step_4/D5_prevalence_persontime.Rmd" "8845f73f7027b331109e7c31c189bc1a"
"content/step_4/D5_prevalence_persontime_masked.Rmd" "a4dddfe958800a499ea5247b2cef8915"
"content/step_5/D3_DU_selection_criteria_from_pregnancies_to_DU_PREGNANCY_COHORT.Rmd" "9d952dab66b3a9e22451bdb151c9b260"
"content/step_5/D3_DU_selection_criteria_from_SAP1_MS_cohort_to_DU_MS_cohort.Rmd" "b2d205aef48746aab1bedf6e9f1ab364"
"content/step_5/D3_SAP1_MS_COHORT.Rmd" "3e24c6676ea4488196f3b285cc44f288"
"content/step_6/D4_DU_MS_COHORT.Rmd" "bb345008641c79c6aa83584ced73506c"
"content/step_6/D4_DU_PREGNANCY_COHORT.Rmd" "42838432ce490bc9710a98d70ec9d6fb"
"content/step_6/D5_DU_flowchart_exclusion_criteria_from_pregnancies_to_DU_PREGNANCY_COHORT.Rmd" "4a650321bdd82c1f69957e90b0c90c51"
"content/step_6/D5_DU_flowchart_exclusion_criteria_from_SAP1_MS_cohort_to_DU_MS_cohort.Rmd" "16c62bb17fbaea1f936f6431da30b866"
"content/step_7/D3_DU_PREGNANCY_COHORT_variables.Rmd" "a0969dd61a384f372912d2e31583b470"
"content/step_8/D5_DU_for_Template_1.Rmd" "bba41e82c8a4dd34841f1c54efd8d220"
"content/step_8/D5_DU_for_Template_2.Rmd" "097d38a2d9f4f9101b9ae9371761689a"
"content/step_9/D4_candidate_matches_MS_non_pregnant.Rmd" "311485aba830438829d3e9460f73dcc0"
"content/step_9/D4_DU_matched_MS_PREGNANCY_COHORT_to_MS_COHORT.Rmd" "7fd287d89bbf194e0de20c8513793980"
"content/step_9/D5_DU_matching_diagnostic.Rmd" "bf3d21799f10ae95019befc15689254c"
